SCHEMBL30748809

SCHEMBL30748809

O=C1N(c2ccc(Oc3ccccc3)cc2)c2nc(Cl)ncc2C12CC2

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 2/20 0.45
CDK2 P24941 2/20 0.45
EGLN1 Q9GZT9 2/20 0.43
MGLL Q99685 1/20 0.41
MARK3 P27448 2/20 0.38
PGR P06401 2/20 0.38
PIN1 Q13526 3/20 0.37
PLCG1 P19174 1/20 0.36
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 2/20 0.35
MMP2 P08253 2/20 0.35
MMP3 P08254 2/20 0.35
MMP9 P14780 2/20 0.35
MMP13 P45452 2/20 0.35
USP2 O75604 1/20 0.35
ALOX15 P16050 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749085 0.84 EGLN1 (0.44) CCNE1CDK2EGLN1MGLLMARK3
SCHEMBL30749103 0.84 EGLN1 (0.44) CCNE1CDK2EGLN1MGLLMARK3
SCHEMBL30749006 0.84 EGLN1 (0.44) CCNE1CDK2EGLN1MGLLMARK3
SCHEMBL30748879 0.75 ALDH1A1 (0.44) MGLLPIN1PLCG1ALDH1A1LMNA
SCHEMBL30748944 0.75 CCNE1 (0.39) CCNE1CDK2ALDH1A1MAPT
SCHEMBL30748962 0.75 LIPE (0.38) CCNE1CDK2MARK3ALDH1A1
SCHEMBL30748803 0.75 CCNE1 (0.39) CCNE1CDK2
SCHEMBL30749030 0.74 PIN1 (0.40) MGLLPIN1PLCG1MAPTMMP2
SCHEMBL30749142 0.74 ALDH1A1 (0.45) MGLLPIN1PLCG1ALDH1A1LMNA
SCHEMBL30749020 0.72 PIN1 (0.40) MGLLPIN1PLCG1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT CCNE1 2310/4885CDK2 680/4885EGLN1 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.